Bli medlem
Bli medlem

Du är här


Prothena to Present Quality of Life Data on AL Amyloidosis at European Hematology Association 21st Congress

Prothena Corporation plc
Press release

Prothena to Present Quality of Life Data on AL Amyloidosis at European
Hematology Association 21st Congress

DUBLIN, Ireland, 2016-05-19 22:05 CEST (GLOBE NEWSWIRE) -- Prothena Corporation
plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the
discovery, development and commercialization of novel protein immunotherapies,
today announced that data from multiple quality of life studies in patients
with AL amyloidosis will be highlighted at The European Hematology Association
(EHA) 21st Congress to be held June 9-12 in Copenhagen, Denmark.

“We look forward to sharing these qualitative and quantitative data that
advances the understanding of the impact of AL amyloidosis on patients’ lives
at the upcoming EHA congress,” commented Dale Schenk, PhD, President and Chief
Executive Officer of Prothena, “Our commitment to the amyloidosis community
involves not only research and development towards the goal of developing a new
therapy indicated for AL amyloidosis, but also a commitment to understanding
the impact of this devastating disease on patients’ quality of life.”

Data that highlights a variety of aspects of quality of life in AL amyloidosis,
including the relative burden of AL amyloidosis on health-related quality of
life for patients, the impact of treatment-related symptoms on treatment
compliance, impact on absenteeism, job productivity and loss, and validity of
psychometric properties of the SF-36v2® Health Survey, will be presented in the
following sessions:

(Abstract #P784) The Relative Burden of AL Amyloidosis on Health-related
Quality of Life

-- Presenter: Spencer Guthrie, Head of Development Affairs, Prothena
Biosciences Inc.
-- Session: Quality of life, palliative care, ethics and health economics 2
-- Date and Time: Saturday, June 11, 2016 from 17:30 -19:00 CET
-- Location: Poster Area (Hall H)

(Abstract #E1445) Treatment History, Tolerability and Impact on Health-Related
Quality of Life in AL Amyloidosis

-- e-Poster presentation

(Abstract #E1458) The Impact of AL Amyloidosis on Absenteeism, Reduced
Productivity and Job Loss

-- e-Poster presentation

(Abstract #E1441) Psychometric Validation of the SF-36V2® Health Survey in an
AL Amyloidosis Population

-- e-Poster presentation

All e-Posters are available Friday, June 10, 9:30 to Saturday, June 11, 19:00

About AL Amyloidosis

Systemic amyloidoses are a complex group of progressive diseases caused by
tissue deposition of misfolded proteins that result in progressive organ
damage. The most common type, AL amyloidosis or primary amyloidosis, involves a
hematological disorder caused by plasma cells that produce misfolded
immunoglobulin light chain resulting in deposits of abnormal AL protein
(amyloid) in the tissues and organs of individuals with this disease. There are
no approved treatments for AL amyloidosis, and none that directly target
potentially toxic forms of the AL protein. AL amyloidosis is a rare disorder
and it is estimated that about 30,000 to 45,000 patients in the U.S. and Europe
suffer from this disease. Both the causes and origins of AL amyloidosis remain
poorly understood. For more information on AL amyloidosis, please visit the
websites of the Amyloidosis Support Group and the Amyloidosis Foundation.

About Prothena

Prothena Corporation plc is a global, late-stage clinical biotechnology company
seeking to fundamentally change the course of progressive diseases with its
clinical pipeline of novel therapeutic antibodies. Fueled by its deep
scientific understanding built over decades of research in protein misfolding
and cell adhesion – the root causes of many serious or currently untreatable
amyloid and inflammatory diseases – Prothena has advanced several drug
candidates into clinical trials while pursuing discovery of additional novel
therapies. Our clinical pipeline of antibody-based product candidates targets
a number of potential indications including AL amyloidosis (NEOD001),
Parkinson’s disease and other related synucleinopathies (PRX002) and
inflammatory diseases including psoriasis (PRX003).

Forward-looking Statements

This press release contains forward-looking statements. These statements relate
to, among other things, our goal to develop a new therapy specifically
indicated for AL amyloidosis. These statements are based on estimates,
projections and assumptions that may prove not to be accurate, and actual
results could differ materially from those anticipated due to known and unknown
risks, uncertainties and other factors, including but not limited to the risks,
uncertainties and other factors described in the "Risk Factors" sections of our
Annual Report on Form 10-K filed with the Securities and Exchange Commission
(SEC) on February 25, 2016 and our subsequent Quarterly Reports on Form 10-Q
filed with the SEC. Prothena undertakes no obligation to update publicly any
forward-looking statements contained in this press release as a result of new
information, future events or changes in Prothena's expectations.


Investors: Tran Nguyen, CFO

Media: Ellen Rose, Head of Communications

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.